Sigma Planning Corp lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,550 shares of the medical instruments supplier’s stock after selling 163 shares during the period. Sigma Planning Corp’s holdings in Becton, Dickinson and were worth $1,477,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently made changes to their positions in BDX. Accel Wealth Management increased its position in shares of Becton, Dickinson and by 100.0% during the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 50 shares in the last quarter. Sierra Capital LLC increased its position in shares of Becton, Dickinson and by 88.7% during the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. Level Financial Advisors Inc. bought a new stake in shares of Becton, Dickinson and during the fourth quarter valued at approximately $26,000. Icapital Wealth LLC bought a new stake in Becton, Dickinson and in the 1st quarter worth approximately $31,000. Finally, Rosenberg Matthew Hamilton grew its position in Becton, Dickinson and by 61.5% in the 1st quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 48 shares during the period. 86.58% of the stock is owned by institutional investors.
A number of equity research analysts have commented on the stock. StockNews.com downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company raised shares of Becton, Dickinson from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a research report on Friday, June 24th. Piper Sandler cut their target price on shares of Becton, Dickinson and from $265.00 to $255.00 in a research report on Thursday, May 5th. Finally, Morgan Stanley lifted their target price on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research report on Monday, April 11th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and has a consensus rating of “Hold” and an average price target of $279.17.
In related news, VP Thomas J. Spoerel sold 443 shares of Becton, Dickinson and stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $260.00, for a total transaction of $115,180.00. Following the transaction, the vice president now owns 1,058 shares in the company, valued at approximately $275,080. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Friday, May 6th. The shares were sold at an average price of $256.00, for a total transaction of $121,600.00. Following the transaction, the executive vice president now owns 3,806 shares in the company, valued at approximately $974,336. The disclosure for this sale can be found here. 0.50% of the stock is currently owned by insiders.
Shares of BDX stock opened at $251.80 on Monday. Becton, Dickinson and Company has a 1 year low of $231.46 and a 1 year high of $280.62. The firm has a fifty-day moving average price of $249.80 and a 200-day moving average price of $258.28. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The company has a market cap of $71.78 billion, a price-to-earnings ratio of 39.72, a PEG ratio of 3.39 and a beta of 0.62.
Becton, Dickinson and (NYSE:BDX – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.20. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The firm had revenue of $5.01 billion during the quarter, compared to the consensus estimate of $4.78 billion. During the same quarter in the previous year, the firm posted $3.19 EPS. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities research analysts expect that Becton, Dickinson and Company will post 11.21 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, June 30th. Investors of record on Thursday, June 9th were paid a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date was Wednesday, June 8th. Becton, Dickinson and’s dividend payout ratio (DPR) is 54.89%.
About Becton, Dickinson and: (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extension sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Featured Articles:
Receive News & Ratings for Becton Dickinson and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and related companies with MarketBeat.com’s FREE daily email newsletter.
.